Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

Overview

This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.

Full Title of Study: “Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 13, 2021

Detailed Description

Subjects eligible for treatment will be those who at baseline, are not actively infected with SARS-CoV-2, have no evidence of prior infection with SARS-CoV- 2 based on serologic testing, and give informed consent for a vaccination with AV-COVID-19. The patient population will include the elderly and others at higher risk for poor outcomes after COVID-19 infection. For this reason, individuals will not be excluded solely on the basis of age, body mass index, history of hypertension, diabetes, cancer, or autoimmune disease. After enrolling for screening, subjects will undergo a nasal swab test to exclude active COVID-19 infection and a rapid test for anti-coronavirus antibodies to exclude pre-existing anti-SARS-CoV-2 antibodies. 50 mL of blood will be collected, from which peripheral blood monocytes will be isolated and differentiated into DC before incubation with SARS-CoV-2 S-protein, during which time the protein is digested into 9 to 25 amino acid peptide sequences presented on the dendrites of DC in conjunction with histocompatibility class I and class II molecules. Safety and quality testing will be performed on a small quantity of the batch, and the remaining AV-COVID-19 will be cryopreserved for shipping to the treatment site. Once the Study Drug is ready, if eligible, the subject will be seen at Study Week-0 for treatment. Prior to injection of the Study Drug, a nasal swab test will be collected to confirm that they are still negative for COVID-19, and blood will be drawn to determine baseline levels of anti-SARS-CoV-2 antibodies. At the treatment site, the product will be thawed and admixed with saline or (saline with GM-CSF), and within 5 hours of thawing, will be injected SC via a 25- gauge needle

Interventions

  • Biological: AV-COVID-19
    • Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
  • Other: GM-CSF
    • GM-CSF as an adjuvant

Arms, Groups and Cohorts

  • Experimental: 0.1 mg antigen, 0 mcg GM-CSF
    • Dendritic cells previously incubated with 0.1 mcg antigen
  • Experimental: 0.33 mg antigen, 0 mcg GM-CSF
    • Dendritic cells previously incubated with 0.33 mcg antigen
  • Experimental: 1.0 mg antigen, 0 mcg GM-CSF
    • Dendritic cells previously incubated with 1.0 mcg antigen
  • Experimental: 0.1 mg antigen, 250 mcg GM-CSF
    • Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
  • Experimental: 0.33 mg antigen, 250 mcg GM-CSF
    • Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
  • Experimental: 1.0 mg antigen, 250 mcg GM-CSF
    • Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
  • Experimental: 0.1 mg antigen, 500 mcg GM-CSF
    • Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
  • Experimental: 0.33 mg antigen, 500 mcg GM-CSF
    • Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
  • Experimental: 1.0 mg antigen, 500 mcg GM-CSF
    • Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF

Clinical Trial Outcome Measures

Primary Measures

  • Incidence and severity of adverse events (safety)
    • Time Frame: 1 week
    • Collection of adverse event incidence and severity in all treatment arms

Secondary Measures

  • Establish optimal dose formulation
    • Time Frame: 1 month
    • Measurement of antibodies in subject blood
  • Duration of detection of antibodies against SARS-CoV-2
    • Time Frame: 1 month
    • Measurement of antibodies in subject blood

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years or older, relatively good health, negative for pre-existing SARS-CoV-2 antibodies, negative for SARS-CoV-2 infection Exclusion Criteria:

  • Active COVID-19 infection by PCR testing, pre-existing SARS-CoV-2 antibodies, pregnant, known hypersensitivity to GM-CSF, known immune deficiency disease, on active treatment with immunosuppressive agent or corticosteroid, participated in previous COVID-19 trial

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Aivita Biomedical, Inc.
  • Collaborator
    • PT AIVITA Biomedika Indonesia
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Robert O Dillman, MD, Study Chair, Aivita Biomedical, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.